NSE's IPO journey dates back to 2016, when it first attempted to file. That attempt stalled for nearly a decade due to regulatory scrutiny, governance concerns, and the co-location controversy. What changed in 2026 was decisive: SEBI issued its No Objection Certificate on January 30, 2026 the mandatory clearance that any market infrastructure institution needs before it can approach the public market.
NSE's board approved the IPO plan on February 6, 2026. A legal challenge to the SEBI NOC was dismissed by the Delhi High Court on February 16, 2026. By March 12, 2026, NSE had appointed MUFG Intime India as registrar and assembled a consortium of 20 Book Running Lead Managers including Kotak Mahindra Capital, JM Financial, Morgan Stanley India, JP Morgan India, HSBC, Citigroup, ICICI Securities, Axis Capital, and SBI Capital Markets the largest banker consortium ever assembled for an Indian IPO.
The DRHP was filed on June 17, 2026. SEBI's review of a filing of this complex typically takes three to four months. That places the earliest possible observation issuance around September to October 2026, with a listing at some point before December 2026 subject to market conditions and regulatory outcomes.
Investors should treat this timeline as a framework for planning, not a guarantee.
The NSE IPO is structured entirely as an Offer for Sale. No fresh equity is being issued. NSE itself will receive none of the proceeds. The offering covers up to 14,89,05,525 equity shares sold by existing shareholders, a dilution of approximately 6% of total equity. The proceeds will go to the selling shareholders in proportion to the shares they offload.
SBI is the largest selling shareholder, proposing to sell up to 2.48 crore shares. Other sellers include institutional names such as GIC Re, New India Assurance, National Insurance, United India Insurance, Bank of Baroda, SHCIL, Canada Pension Plan Investment Board, and Morgan Stanley. LIC, the largest single shareholder at a reported 10.72% stake, is not participating in this OFS. Neither are Premji Invest or investor Radhakishan Damani.
Because NSE cannot list its shares on its own exchange, the listing will happen on BSE, subject to regulatory approvals.
The DRHP also discloses three years of audited financials. Total income peaked at Rs 19,176.83 crore in FY25, then eased to Rs 18,713.37 crore in FY26. Revenue from operations followed the same pattern, declining from Rs 17,140.68 crore in FY25 to Rs 16,601.31 crore in FY26. Net profit for FY26 came in at Rs 10,302.06 crore, a 15.5% decline from Rs 12,188 crore in FY25. The DRHP attributes this to lower transaction charge income, reduced clearing and settlement income, higher expenses, and certain exceptional items. This is the single most important data point that investors in NSE unlisted shares should absorb before making any decision.
The NSE unlisted share price was quoted in a buy-sell range of approximately Rs 2,040 to Rs 2,075 as of June 24–25, 2026, with a reported 52-week range of Rs 1,891 to Rs 2,400 per share. These are OTC market quotes bilateral, informal, and not independently verified. They are not exchange-traded prices.
What the DRHP filing does to the unlisted price is nuanced. It confirms that the IPO is no longer a rumour, which tends to reduce the uncertainty discount that some buyers had been pricing in. Investors who were waiting for formal documentation before transacting may now be more active, which increases demand-side pressure in a market that is already thin.
At the same time, the DRHP introduces hard financial data that replaces speculation. When unlisted market participants previously assumed revenue growth, they were working on estimates. Now the DRHP shows FY26 revenue and profit both declining. For investors who were pricing in aggressive growth expectations, this is corrective information.
There is also a structural dynamic to watch: some shareholders who had been waiting for the DRHP as a trigger to exit may now increase supply. Whether new demand absorbs this supply determines near-term price direction and in a low-liquidity OTC market, even small changes in the buyer-seller balance can move the quoted price materially.
The gap between the current unlisted price and the eventual IPO price band deserves separate attention. The unlisted market implies a valuation in the range of Rs 5 lakh crore based on current prices and total share count. At NSE's FY26 net profit of Rs 10,302 crore, that implies a P/E of approximately 49x. Whether institutional investors will accept this multiple given the FY26 earnings decline and the regulatory risk profile is what the book-building process will determine. The IPO price band, once announced, may be at, above, or below current unlisted prices. No one knows in advance.
If you already hold NSE shares in your demat account, the DRHP filing creates a specific action list.
Verify your holding. Confirm that your shares are correctly reflected under ISIN INE721I01024 in your NSDL or CDSL demat account. NSE has historically required a Right of First Refusal process for share transfers. If you acquired shares and did not go through a formal ROFR clearance, verify the status of the transfer immediately.
Understand OFS eligibility. Only shareholders who held shares continuously for at least one year prior to the DRHP filing date of June 17, 2026 may be eligible to participate in the OFS as selling shareholders. If you are not a named selling shareholder, you will hold through listing and become subject to the post-listing lock-in rules.
Calculate your adjusted acquisition cost. NSE executed a 4:1 bonus issue, meaning every original share became five shares post-bonus. If you bought 100 shares at Rs 6,500 each (pre-bonus), your total cost was Rs 6,50,000. Post-bonus, you hold 500 shares. Your adjusted cost per share is Rs 1,300. For tax purposes, the bonus shares carry a zero acquisition cost, which means the gain on all 400 bonus shares at the time of sale is taxed in full.
Plan for lock-in. For retail and HNI investors who acquired NSE shares in the pre-IPO market, SEBI's 2021 regulations impose a six-month lock-in from the listing date. You cannot sell immediately after the exchange lists. Factor this into your liquidity planning if the IPO lists in late 2026, your earliest exit opportunity may be mid-2027.
Compute your tax position now. Unlisted shares held for more than 24 months qualify for LTCG treatment at 12.5% without indexation (as per Finance Act 2024). Shares held for 24 months or less are taxed at your applicable slab rate. Run the numbers with a chartered accountant before the IPO event, not after.
| Factor | Good Sign | Red Flag |
| Seller's demat details | ISIN INE721I01024 confirmed in statement | Seller cannot provide demat account proof |
| ROFR status | Transfer formally cleared or waived | Shares not yet in buyer's demat |
| OTC price vs market | Within Rs 40–50 of current platform quotes | Significantly below market with no clear reason |
| Holding period | Acquired over 24 months ago (LTCG eligible) | Recent acquisition; tax treatment unclear |
| Liquidity planning | Can hold 12–18 months comfortably | Needs exit within 6 months |
| Financial review | FY26 financials from DRHP reviewed | Decision based on sentiment only |
| Lock-in awareness | 6-month post-listing lock-in factored in | Expects to sell day one after listing |
| Tax consultation | CA has reviewed cost basis and tax liability | No tax planning done |
Treating the DRHP filing as IPO approval is the most frequent error. SEBI still needs to review the document, issue observations, and clear the RHP before the offering can open. That process takes months.
Assuming the OTC price predicts the IPO price band is equally problematic. Unlisted market quotes and institutional book-building are completely different mechanisms. The eventual price band reflects institutional demand, peer comparisons, and market conditions at the time of the offer.
Ignoring the FY26 financial decline is a third mistake. The DRHP discloses a 15.5% net profit decline; this needs to be part of the investment thesis, not a footnote.
Not planning for the lock-in creates real problems. Investors who assume immediate post-listing liquidity and discover the six-month restriction only after listing find themselves holding an illiquid position at the worst possible time.
Supremus Angel provides investors access to research-based information on NSE unlisted shares, documentation assistance, and market updates as the IPO process progresses. The platform helps investors understand DRHP disclosures, navigate demat transfer and ROFR requirements, and stay current on SEBI review timelines. No return projections are offered and no guarantees are made.
1. Can I still buy NSE unlisted shares after the DRHP filing?
Yes, The DRHP filing does not stop investors from buying NSE unlisted shares. Transactions can continue in the OTC market through registered intermediaries, provided the shares are transferred to your demat account following the required procedures.
2. Does the DRHP mean the NSE IPO is confirmed?
Not yet. Filing the DRHP is an important milestone, but SEBI must review the document and issue its observations before the IPO can proceed. The final launch will also depend on regulatory approvals and market conditions.
3. Why are NSE unlisted shares priced differently from the IPO price?
The unlisted share price is determined through private OTC transactions between buyers and sellers, whereas the IPO price is decided through the book-building process based on institutional and retail investor demand.
4. What should I check before buying NSE unlisted shares?
Verify the seller's ownership, confirm the shares are held under the correct ISIN, review the latest financial information disclosed in the DRHP, and understand the tax implications and potential lock-in period before investing.
5. Will existing NSE shareholders be able to sell immediately after listing?
Not necessarily. Many pre-IPO investors may be subject to a six-month lock-in period after the shares are listed, depending on applicable SEBI regulations.
